At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Venetoclax (drug), Obinutuzumab (drug)
- How long the study runs
- Study runs about 82 months (dates as stated)
- About the drug or intervention
- Venetoclax — drug: Oral tablet · Obinutuzumab — drug: Intravenous (IV) infusion
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is for adults whose chronic lymphocytic leukaemia (CLL) — a type of blood cancer — has come back after earlier treatment. It looks at how well oral venetoclax (a tablet) works alongside intravenous (IV, given into a vein) obinutuzumab, and at any side effects. The study is run by AbbVie.
Who can take part
- You have a confirmed diagnosis of CLL that needs treatment, based on accepted 2018 guidelines.
- You finished a first course of treatment that included venetoclax plus another antibody medicine (with or without an extra drug), and it worked — your cancer got better.
- A certain amount of time has passed since your last venetoclax dose and your disease coming back: more than 24 months for one group, or 12 to 24 months for another group.
Who may not be able to
- You have had any other treatment for CLL since finishing your earlier venetoclax-based treatment.
What taking part involves
- • Taking venetoclax as a tablet by mouth
- • Receiving obinutuzumab through a drip into a vein (IV)
Time commitment: Not stated — ask the trial team about how long the study lasts, how many visits are needed, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 75
- Started
- 2022-03-28
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for chronic lymphocytic leukemia (cll)
- • Phase2 - 75 participants
- • Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with chronic lymphocytic leukemia (cll)
Where?
- • Blackpool - Blackpool Victoria Hospital /ID# 267280
- • Norwich - Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 250733
- • Leeds - Leeds Teaching Hospitals NHS Trust /ID# 250732
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +/- X will be enrolled in the study in approximately 60 sites worldwide. Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to...
- ✓More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease...
Who cannot take part
- ✗\- Received intervening treatment for CLL after completing previous treatment with a venetoclax + anti-CD20 antibody...
See the full criteria
Where Is This Study? (3 UK sites)
Blackpool Victoria Hospital /ID# 267280
Blackpool FY3 8NR, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 250733
Norwich NR4 7UY, United Kingdom
Leeds Teaching Hospitals NHS Trust /ID# 250732
Leeds LS9 7TF, United Kingdom
How to Get in Touch
ABBVIE CALL CENTER
Sponsor contactCONTACT